Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Medical-device maker said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

The man who acquired Sound United and founded US Health Company Masimo has been sacked by his own board, and to top that that ...

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

The consensus among analysts is an Outperform trajectory for Inspire Medical Systems ... All You Need to Know About Masimo Masimo Corp is a global technology company. The company's segment ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.